CA-SCIENTIST.COM
Scientist.com, the life science industry’s leading online marketplace for outsourced research, announced today the appointment of Mark Herbert to its senior leadership team. As the company’s chief business officer, he will focus on continuing the company’s rapid growth and expansion into new research areas and countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180925005077/en/
“The Scientist.com research sourcing platform is revolutionizing how medical research is done,” said Mark Herbert, Scientist.com’s new Chief Business Officer. “I look forward to helping establish new partnerships, expand existing partnerships and advance our goal of delivering an innovative and disruptive marketplace to the global life sciences community.”
Mark has 20+ years’ experience in pharmaceutical and biotech research across multiple platforms and therapeutic areas. He last served as Interim President of Arcturus Therapeutics, a public company, where he led operations, business development and alliance management activities. While at Arcturus, Mark established strategic partnerships with pharmaceutical and biotech companies, in-licensed key intellectual property and secured non-dilutive funding through the Cystic Fibrosis Foundation. Previously, he was Head of U.S. Business Development and Sales at STA Pharmaceutical Co., Ltd., WuXi AppTec’s small molecule development and manufacturing division, where he was responsible for all North American business development. Mark also previously served as Director of Pharmaceutical Sciences at Aragon Pharmaceuticals, Inc. which was acquired by Johnson & Johnson in 2013. He is an author or inventor on over 35 peer-reviewed manuscripts and patents and has led or contributed to the submission of 13 investigational new drug (IND) applications and one new drug application (NDA).
“Mark is an outstanding scientist-entrepreneur with a rare combination of technical talent and business development acumen,” said Kevin Lustig, PhD, Scientist.com’s CEO and Founder. “His strong scientific background and business expertise will help us build the right relationships and continue our rapid expansion into Europe, Japan and China.”
About Scientist.com
Scientist.com is the world’s leading marketplace for outsourced research. The marketplace simplifies the entire research sourcing process, saving time and money and providing access to the latest innovative tools and technologies while maintaining full compliance with an organization’s procurement policies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, VWR and the US National Institutes of Health (NIH). Since its founding in 2007, Scientist.com has raised more than $33 million from Leerink Transformation Partners, 5AM Ventures, Heritage Provider Network, Bootstrap Ventures and Hollywood producer Jack Giarraputo among others. Visit scientist.com to learn more.
Join Scientist.com on social media: YouTube , LinkedIn , Twitter , Facebook , Google+ and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20180925005077/en/
Contact:
Scientist.com Sean Preci, +1 858 455-1300 ext. 401 Director of Communications marketing@scientist.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)17.11.2025 07:00:00 CET | Press release
Pending the European Commission decision, Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide will represent an important new therapeutic option from second line for patients with follicular lymphoma (FL) in EuropeIn Western countries, relapsed or refractory FL affects 2-4 out of every 100,000 people1The positive Committee for Medicinal Products for Human Use (CHMP) recommendation is based on data from the Phase 3 inMIND trial which showed patients with relapsed or refractory FL achieved significantly improved progression-free survival with Minjuvi in combination with rituximab and lenalidomide2 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at
ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline17.11.2025 07:00:00 CET | Press release
At ASDS 2025, Galderma unveiled pivotal new data from its range of pioneering Restylane® hyaluronic acid (HA) injectables, highlighting its versatility in improving the chin profile with Restylane Lyft™, temple volume with investigational Restylane Contour™* and skin quality in the décolletage (neckline) with investigational Restylane Skinboosters™*1-3 Nine-month results from a first-of-its-kind clinical trial were presented, reinforcing that the treatment regimen of Restylane Lyft or Restylane Contour with Sculptra® delivers sustained aesthetic facial improvements for patients experiencing facial aesthetic changes after medication-driven weight loss4 The company also presented new phase III data on its investigational product Relfydess™ (RelabotulinumtoxinA)* relating to its rapid onset as early as day one and long duration of effect on frown lines and crow’s feet5 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Inje
UBS and Ant International Partner on Blockchain-Based Real-Time Cross-Border Payments Settlement and Liquidity Management17.11.2025 05:42:00 CET | Press release
UBS has entered a strategic partnership with Ant International, a leading global digital payment, digitisation, and financial technology provider, to explore innovations in blockchain-based tokenised deposits to support Ant International’s global payments settlement and liquidity management. Both parties signed a Memorandum of Understanding (MoU) at UBS’s flagship office at 9 Penang Road in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251116743090/en/ From left to right: Young Jin Yee, Co-Head UBS Global Wealth Management Asia Pacific and Country Head Singapore, Kay Tin Khoo, Head Corporate Institutional Clients Asia Pacific, UBS, Kelvin Li, General Manager of Platform Tech at Ant International, and Douglas Feagin, President of Ant International at the MoU signing ceremony at UBS Singapore office at 9 Penang Road. Under the MoU, Ant International will leverage UBS Digital Cash, a blockchain-based payment platfor
Nitto Extends Partnership with the ATP Until 203017.11.2025 04:24:00 CET | Press release
Nitto Denko Corporation (Headquarters: Osaka, Japan; President: Hideo Takasaki; hereafter “Nitto”)(TOKYO:6988) is pleased to announce the extension of its partnership with the ATP for an additional five years, through 2030. Under this renewed agreement, Nitto will continue its role as the Title Partner of the Nitto ATP Finals, the season-ending championship, in collaboration with the ATP and the Italian Tennis and Padel Federation (FITP). By sponsoring this tournament, recognized as one of the most sustainable events on the ATP Tour, Nitto aims to inspire and amaze while pursuing further growth as a global company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251116197903/en/ Nitto Extends Partnership with the ATP Until 2030 : ©Corinne Dubreuil/ATP Tour Since 2017, Nitto has served as the Title Partner of the Nitto ATP Finals―the year-end climax of the men's professional tennis circuit featuring the world’s the top eight s
AIT Worldwide Logistics’ Global Expansion Continues With First Facility in Indonesia17.11.2025 04:01:00 CET | Press release
Jakarta office launches in response to demand for logistics expertise in Southeast Asia As part of its ongoing organic expansion strategy, global supply chain solutions leader, AIT Worldwide Logistics, opened its first office in Jakarta, Indonesia. The new facility represents the eighth country in the AIT-Asia network and exemplifies the company’s adaptability and flexibility in response to customer demands in the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251116717860/en/ Teammates gathered to celebrate the grand opening of AIT-Jakarta. According to AIT’s Chief Strategy Officer, Greg Weigel, the team in Jakarta will collaborate with AIT’s expansive global network to quickly customize sea, air and road solutions unique to each client’s organizational needs, with a particular focus on the region’s flourishing industrial, technology and telecommunications sectors. “Jakarta is a pivotal market for us as we continue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom